Evidence map›Paper›PMID 38613667›Full record

SynthesisDiabetologia2024

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, Athina Stamati, Panagiota Kakotrichi, Aris Liakos, Despoina Vasilakou, Nikolaos Kakaletsis, Apostolos Tsapas, Eleni Bekiari

Open access · hybridAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 8 pooled it
30.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 8 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Comparative effectiveness of semaglutideFrontiers in pharmacology · 2025
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. The 'Obesity First' approach: Redefining the future of healthcare.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Thomas KaragiannisClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. tkaragian@auth.gr.ORCID http://orcid.org/0000-0001-5242-0574
Konstantinos MalandrisClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-5134-2401
Ioannis AvgerinosClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0003-2232-1342
Athina StamatiSchool of Medicine, Faculty of Health Science, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-4827-2350
Panagiota KakotrichiClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0003-2544-9819
Aris LiakosClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0003-3261-2979
Despoina VasilakouClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0009-0007-6701-0712
Nikolaos KakaletsisClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-5263-1803
Apostolos TsapasClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0003-0221-4072
Eleni BekiariClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0001-9975-3835
Aristotle University of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisWe conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus.

methodsWe searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA

resultsA total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA CONCLUSIONS/

interpretationOur data show that s.c. tirzepatide had a more pronounced effect on HbA REGISTRATION: PROSPERO registration no. CRD42022382594.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsRandomized Controlled Trials as TopicAdultBlood GlucoseFemaleGastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorGlycated HemoglobinHumansInjections, SubcutaneousMaleSemaglutideTirzepatideBlood GlucoseGastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsSemaglutideTirzepatideGIP/GLP-1 receptor agonistGLP-1 receptor agonistNetwork meta-analysisSemaglutideSystematic reviewTirzepatide

Identifiers

PMID38613667
PMCPMC11153294
OpenAlexW4394785699

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.